Benralizumab clinical trials
Also written Fasenra and MEDI-563.
How each study uses benralizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the benralizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Nov 2017 · FASENRA · BLA 761070 (FDA, Drugs@FDA)
- European Union
- 8 Jan 2018 · Fasenra · EMEA/H/C/004433 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
66 studies that test it; most in 2019 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 46 · Other 21
AstraZeneca (38) · MedImmune LLC (6) · McMaster University (2) · Kyowa Kirin Co., Ltd. (2) · Aristotle University Of Thessaloniki (1) · Memorial Sloan Kettering Cancer Center (1) · Humanitas Clinical and Research Center (1) · NHS Greater Glasgow and Clyde (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test benralizumab, phase 3 first.
- Dec 2026A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaPhase 3 · AstraZeneca
- Jun 2027Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and EndotypingPhase 4 · University of California, San Diego
- Sep 2027Fasenra: An Asthma StudyPhase 4 · Endeavor Health
Studies
Open first, then newest update. How each study uses benralizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 67
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentRecruitingPhase 3AstraZenecaNCT07444567Written as Benralizumab
- A Trial to Investigate Benralizumab in Children With Eosinophilic DiseasesRecruitingPhase 3AstraZenecaNCT06512883Written as Benralizumab
- Fasenra: An Asthma StudyEnrolling by invitationPhase 4Endeavor HealthNCT07654842Written as Benralizumab
- Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)Not yet recruitingPhase 2University Hospital, LilleNCT06734884Written as Benralizumab 30 MG/ML [Fasenra]
- Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and EndotypingRecruitingPhase 4University of California, San DiegoNCT06385236Written as Benralizumab
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaActive, not recruitingPhase 3AstraZenecaNCT05692180Written as Benralizumab
- Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsCompletedPhase 4AstraZenecaNCT03953300Written as Benralizumab
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.Active, not recruitingPhase 3AstraZenecaNCT04157348Written as Benralizumab
- BenRalizumab Effect on Airway Remodeling in Severe asTHmaCompletedPhase 4Aristotle University Of ThessalonikiNCT06288516Written as Benralizumab 30 mg/ml
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentCompletedPhase 3AstraZenecaNCT06750289Written as benralizumab
- STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic AsthmaCompletedPhase 3AstraZenecaNCT06465485Written as Benralizumab
- A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)Active, not recruitingPhase 3AstraZenecaNCT04191304Written as Benralizumab
- Study of Benralizumab in People With Skin Side Effects Caused by Cancer TherapiesCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT04552288Written as Benralizumab
- Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)TerminatedPhase 3AstraZenecaNCT04157335Written as Benralizumab 30 mg
- Effect of Benralizumab in Atopic DermatitisCompletedPhase 2McMaster UniversityNCT03563066Written as Benralizumab
- Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsCompletedPhase 3AstraZenecaNCT04053634Written as Benralizumab
- Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis BronchiectasisTerminatedPhase 3AstraZenecaNCT05006573Written as Benralizumab
- Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)TerminatedPhase 3AstraZenecaNCT05251909Written as Benralizumab
- BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory ImagingCompletedPhase 4AstraZenecaNCT05552508Written as Benralizumab
- A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With BenralizumabCompletedPhase 4AstraZenecaNCT04159519Written as Fasenra®
See all 67 studies that test benralizumab →
Given beside what is tested · 2 — benralizumab is usual care or a partner of the new treatment
- Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRIActive, not recruitingNot applicableDr. Grace ParragaNCT03733535Written as Benralizumab
- A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast CancerTerminatedPhase 2Memorial Sloan Kettering Cancer CenterNCT05966584Written as Benralizumab
As the comparator · 1 — what is tested is compared with benralizumab
Codes
What other systems call benralizumab · ClinicalTrials.gg INT006028
- MeSH (NLM) C571386benralizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 71492GE1FXBENRALIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1989100Confirmed FDA, Wikidata
- Wikidata Q3638304benralizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88594BenralizumabOne source FDA
- DrugBank DB12023One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571386 | benralizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 71492GE1FX | BENRALIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1989100 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3638304 | benralizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88594 | Benralizumab | One source FDA |
| DrugBank | DB12023 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.